Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(22%)
Results Posted
50%(1 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
6
67%
Ph phase_3
2
22%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)
Other(2)

Detailed Status

Active, not recruiting2
unknown2
Completed2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 32 (22.2%)

Trials by Status

active_not_recruiting222%
withdrawn111%
unknown222%
completed222%
terminated222%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

NCT01244789
completedphase_1

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

NCT03245892
terminatedphase_2

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

NCT04527900
withdrawnphase_2

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

NCT05743270
unknownphase_2

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

NCT03935256
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01244789Phase 2

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Active Not Recruiting
NCT03245892Phase 1

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Completed
NCT04527900Phase 2

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

Terminated
NCT05743270Phase 2

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn
NCT03935256Phase 2

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Unknown
NCT01057069Phase 2

Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

Active Not Recruiting
NCT00050960Phase 3

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Completed
NCT01570582Phase 2

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Unknown
NCT00273507Phase 3

Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9